Evidence map›Paper›PMID 34903929›Full record

ReviewVeterinary world2021

The therapeutic potential of the novel angiotensin-converting enzyme 2 in the treatment of coronavirus disease-19.

Ademola Adetokunbo Oyagbemi, Temitayo Olabisi Ajibade, Yapo Guillaume Aboua, Idayat Titilayo Gbadamosi, Aduragbenro Deborah A Adedapo, Abimbola Obemisola Aro, Olumuyiwa Abiola Adejumobi, Emma Thamahane-Katengua, Temidayo Olutayo Omobowale, Olufunke Olubunmi Falayi and 12 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Veterinary world, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 5 countries.

Ademola Adetokunbo OyagbemiDepartment of Veterinary Physiology and Biochemistry, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
Temitayo Olabisi AjibadeDepartment of Veterinary Physiology and Biochemistry, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
Yapo Guillaume AbouaDepartment of Health Sciences, Faculty of Health and Applied Sciences, Namibia University of Science and Technology, Private Bag 13388, Namibia.
Idayat Titilayo GbadamosiDepartment of Botany, Faculty of Science, University of Ibadan, Nigeria.
Aduragbenro Deborah A AdedapoDepartment of Pharmacology and Therapeutics, University of Ibadan, Nigeria.
Abimbola Obemisola AroDepartment of Agriculture and Animal Health, College of Agriculture and Environmental Sciences, University of South Africa, Florida, South Africa.
Olumuyiwa Abiola AdejumobiDepartment of Veterinary Medicine, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
Emma Thamahane-KatenguaDepartment of Health Information Management, Botho University, Faculty of Health and Education, Botswana.
Temidayo Olutayo OmobowaleDepartment of Veterinary, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
Olufunke Olubunmi FalayiDepartment of Veterinary Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
Taiwo Olaide OyagbemiDepartment of Veterinary Parasitology and Entomology, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
Blessing Seun OgunpoluDepartment of Veterinary, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
Fasilat Oluwakemi HassanDepartment of Veterinary Physiology and Biochemistry, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
Iyanuoluwa Omolola OgunmiluyiDepartment of Veterinary Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
Olufunke Eunice Ola-DaviesDepartment of Veterinary Physiology and Biochemistry, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
Adebowale Benard SabaDepartment of Veterinary Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
Adeolu Alex AdedapoDepartment of Veterinary Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
Sanah Malomile NkadimengDepartment of Paraclinical Science, Phytomedicine Programme, University of Pretoria, Faculty of Veterinary Science, Old Soutpan Road, Onderstepoort, 0110, South Africa.
Lyndy Joy McGawDepartment of Paraclinical Science, Phytomedicine Programme, University of Pretoria, Faculty of Veterinary Science, Old Soutpan Road, Onderstepoort, 0110, South Africa.
Prudence Ngalula Kayoka-KabongoDepartment of Agriculture and Animal Health, College of Agriculture and Environmental Sciences, University of South Africa, Florida, South Africa.
Momoh Audu YakubuDepartment of Environmental and Interdisciplinary Sciences, College of Science, Engineering and Technology, Vascular Biology Unit, Center for Cardiovascular Diseases, Texas Southern University, Houston, TX, USA.
Oluwafemi Omoniyi OguntibejuDepartment of Biomedical Sciences, Phytomedicine and Phytochemistry Group, Oxidative Stress Research Centre, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville 7535, South Africa.
University of Ibadan · NGOnderstepoort Veterinary Academic Hospital · ZAUniversity of South Africa · ZABotho University · BWCape Peninsula University of Technology · ZANamibia University of Science and Technology · NATexas Southern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of coronavirus disease 2019 (COVID-19). This virus has become a global pandemic with unprecedented mortality and morbidity along with attendant financial and economic crises. Furthermore, COVID-19 can easily be transmitted regardless of religion, race, sex, or status. Globally, high hospitalization rates of COVID-19 patients have been reported, and billions of dollars have been spent to contain the pandemic. Angiotensin-converting enzyme (ACE) 2 is a receptor of SARS-CoV-2, which has a significant role in the entry of the virus into the host cell. ACE2 is highly expressed in the type II alveolar cells of the lungs, upper esophagus, stratified epithelial cells, and other tissues in the body. The diminished expressions of ACE2 have been associated with hypertension, arteriosclerosis, heart failure, chronic kidney disease, and immune system dysregulation. Overall, the potential drug candidates that could serve as ACE2 activators or enhance the expression of ACE2 in a disease state, such as COVID-19, hold considerable promise in mitigating the COVID-19 pandemic. This study reviews the therapeutic potential and pharmacological benefits of the novel ACE2 in the management of COVID-19 using search engines, such as Google, Scopus, PubMed, and PubMed Central.

Indexed as

ACE2COVID-19hypertensionlung injuryRenin-angiotensin systemSARS-CoV-2

Identifiers

PMID34903929
PMCPMC8654738
OpenAlexW3210828028

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.